Metagenomi Therapeutics, Inc. to Participate in the Chardan 10th Annual Healthcare Conference
Key Highlights
- ➤Metagenomi CEO Jian Irish to join Chardan genome-editing panel October 20, 2026
- ➤MGX-001 targets hemophilia A with one-time treatment and durable gene expression
- ➤Metagenomi intends to expand its pipeline using site-specific genome editing capabilities
Expert Statements
Jian Irish, President and Chief Executive Officer of Metagenomi Therapeutics
“The supplied article contains no direct quote or clearly attributed statement from Jian Irish.”
EMERYVILLE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that Jian Irish, Ph.D., M.B.A., President and Chief Executive Officer of the Company, will participate in a panel discussion titled “Genome Editing: Next-Wave Platforms Beyond CRISPR 1.0” at the Chardan 10th Annual Healthcare Conference on Tuesday, October 20, 2026, at 10:30 a.m. ET, being held in New York, NY.
A live webcast of the event will be made available on the “News & Events” page in the Investors section of the Company’s website at https://ir.metagenomi.co/news-events/events.
Get started
Create a free account to read the full story.